Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX -3.85%20 3-Year EBITDA Growth Rate is 70.10% as of Dec. 2025, which is at its 10-year median of 70.10. GuruFocus rates ASX:LDX with a GF Score™ of 20/100 and a GF Value™ of A$0.03 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 94.22% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 70.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lumos Diagnostics Holdings was 70.10% per year. The lowest was 70.10% per year. And the median was 70.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lumos Diagnostics Holdings 3-Year EBITDA Growth Rate Related Terms
ASX:LDX vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 70.10% mean?
Lumos Diagnostics Holdings (ASX:LDX) has a 3-Year EBITDA Growth Rate of 70.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lumos Diagnostics Holdings and its competitors. This is near median its historical median of 70.10. Over the past decade, Lumos Diagnostics Holdings' 3-Year EBITDA Growth Rate has ranged from 70.10 to 70.10. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #40 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 5.8%.
Is Lumos Diagnostics Holdings' 3-Year EBITDA Growth Rate too high?
Lumos Diagnostics Holdings' current 3-Year EBITDA Growth Rate of 70.10% is near median its 10-year median of 70.10. Over the past 10 years, this metric has ranged from a low of 70.10 to a high of 70.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Lumos Diagnostics Holdings' value of 70.10% is 754.9% above this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #40 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #40 out of 692 companies for 3-Year EBITDA Growth Rate. This places Lumos Diagnostics Holdings in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Lumos Diagnostics Holdings' value of 70.10% is 754.9% above this benchmark. Historically, Lumos Diagnostics Holdings' own 3-Year EBITDA Growth Rate has ranged from 70.10 to 70.10 over the past decade. While the company's 10-year median is 70.10 vs. the industry median of 8.20, Lumos Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current 3-Year EBITDA Growth Rate of 70.10% is 754.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current 3-Year EBITDA Growth Rate is 70.10%, which is near median its own 10-year median of 70.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.13 — trading 316.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 70.10%, which is near median its 10-year median of 70.10 and 754.9% above the Medical Devices & Instruments industry median of 8.20. Lumos Diagnostics Holdings' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current 3-Year EBITDA Growth Rate is 70.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.13 is trading 316.7% above its estimated GF Value™ of A$0.03.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
3-Year EBITDA Growth Rate: 70.10% (near median its 10-year median of 70.10)
GF Value™: A$0.03 vs. price of A$0.13 (316.7% above fair value)
Industry Position: 754.9% above the Medical Devices & Instruments median (#40 of 692)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
20GF Score
Get the complete analysis for ASX:LDX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
